Skip to Main Content

Paper Details

CDCP1 overexpression drives prostate cancer progression and can be targeted in vivo.
J Clin Invest
26
2020
CDCP1, CRPC, CUB domain-containing protein 1, MAPK, PTEN, SFKs, SRC, SRC family kinases, androgen, androgens, anti-CDCP1, cancer, castration-resistant prostate cancer, metastatic prostate cancer, metastatic prostate tumors, prostate cancer, tumor, tumor suppressor gene PTEN
Author NameAffiliation
Jean-Philippe TheurillatInstitute of Oncology Research (IOR), Oncology Institute of Southern Switzerland (IOSI)
Jean-Philippe TheurillatUniversita' della Svizzera Italiana
Adam SharpDivision of Clinical Studies, Institute of Cancer Research
Wei YuanDivision of Clinical Studies, Institute of Cancer Research
Wei YuanRoyal Marsden NHS Foundation Trust
Peter J WildInstitute of Pathology and Molecular Pathology, University Hospital Zurich
Holger MochInstitute of Pathology and Molecular Pathology, University Hospital Zurich
Holger MochInstitute of Pathology and Molecular Pathology, University Hospital Zurich
Johann S de BonoDivision of Clinical Studies, Institute of Cancer Research
Johann S de BonoRoyal Marsden NHS Foundation Trust
  • 1 - 10

Datasets

Release 1.2